BioNTech SE Q4 FY2024 earnings call

• Oncology: Identified key pan-tumor programs including FixVac, iNeST, and BNT327; initiated Phase 2 trial for autogene cevumeran in bladder cancer; published FixVac trial data; advanced BNT327 trials in small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer.
• Acquisition: Completed acquisition of Biotheus to accelerate BNT327 development, build clinical organization in China, and leverage antibody technology.
• Infectious disease: Maintained global market share of COVID-19 vaccine; advanced next-generation and combination vaccines in clinical development.
• Financials: 2024 revenues were ~EUR2.8 billion; net loss was EUR665 million; cash position at year-end was EUR17.4 billion.

BioNTech's segments include oncology and infectious disease. In 2024, revenues were approximately EUR2.8 billion, down from 2023 due to lower COVID-19 vaccine market demand. Oncology focuses on mRNA cancer immunotherapies (FixVac, iNeST) and bispecific antibody BNT327. Infectious disease involves advancing COVID-19 and next-generation vaccines. R&D expenses for 2024 were approximately EUR2.3 billion, driven by investment in priority programs.

• 2025 revenue expected in range of EUR1.7 billion to EUR2.2 billion, assuming stable vaccination rates, pricing, and market share.
• R&D expenses预计 to be in range of EUR2.6 billion to EUR2.8 billion for priority programs like BNT327.
• SG&A expenses预计 to be in range of EUR650 million to EUR750 million for commercial build-out.
• Capital expenditures预计 to be in range of EUR250 million to EUR350 million for manufacturing and IT investments.

• Legal IP disputes: Uncertainty around timing of outcomes in ongoing legal cases related to IP.
• Vaccine market changes: Potential impacts of evolving public sentiment on mRNA technology and competitive pressures in vaccine market.

Q: About legal IP cases and upcoming outcomes.

A: Jens and Ryan mentioned referring to the 20-F for details and confidence in the strength of BioNTech's IP.

Q: FixVac data in melanoma.

A: Ozlem and Ugur explained FixVac's successful trial in relapsed/refractory melanoma vs iNeST's challenges in metastatic setting, emphasizing focus on adjuvant setting.

Q: BNT327 trial enrollment and differentiation.

A: Ryan, Ugur, and Ozlem discussed clinical development strategy, targeting right patient groups, and potential combinations with ADCs for differentiation.

Q: 327 trial data expectations.

A: Ozlem and Ugur talked about upcoming PFS and OS data in small cell lung cancer trials.

Q: 2025 revenue guidance and Sanofi impact.

A: Jens discussed vaccination stability, write-offs due to product returns, and potential competitive pressures from Sanofi.

Q: 327 study details.

A: Ozlem explained the size and patient population coverage of the non-small cell lung cancer study, including non-squamous and squamous populations.

Q: COVID-19 ACIP decision.

A: Ryan said BioNTech is closely following the policy environment for COVID-19 vaccines in the US